Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266291 | 0.90 | MMP13 (1.00) | MMP13HDAC6 | |
| SCHEMBL4258003 | 0.86 | MMP13 (1.00) | MMP13 | |
| SCHEMBL4265613 | 0.85 | MMP13 (0.78) | MMP13HDAC6 | |
| SCHEMBL4266998 | 0.82 | MMP13 (0.70) | MMP13HDAC6 | |
| SCHEMBL4260427 | 0.78 | MMP13 (0.75) | MMP13HDAC6 | |
| SCHEMBL4266309 | 0.77 | MMP13 (0.78) | MMP13HDAC6 | |
| SCHEMBL4268996 | 0.77 | MMP13 (1.00) | MMP13 | |
| SCHEMBL4269083 | 0.76 | MMP13 (0.79) | MMP13HDAC6 | |
| SCHEMBL4262530 | 0.76 | MMP13 (0.68) | MMP13HDAC6 | |
| SCHEMBL4262856 | 0.75 | MMP13 (0.71) | MMP13HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | claimed |
| CN-1674892-A | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-09-28 | — | — | CN | claimed |
| EP-1536784-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | claimed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| CN-100379415-C | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2008-04-09 | — | — | CN | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| CN-1674892-A | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-09-28 | — | — | CN | disclosed |
| EP-1536784-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP2, MMP3 | MMP13 8/4885HDAC6 53/4885 |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | MMP13 1/4885HDAC6 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.